{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:32:29Z","timestamp":1786627949551,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12564-6","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:47:16Z","timestamp":1786625236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunometabolic Effects of SGLT2 Inhibitors on the Th17\/Treg Axis: Mechanisms, Evidence, and Implications for Therapeutic Repurposing"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8327-0906","authenticated-orcid":false,"given":"Hamza","family":"Alasbily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi M.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"12564_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"12564_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30204125","volume":"30","author":"J Hanke","year":"2025","unstructured":"Hanke J, Romejko K, Niemczyk S (2025) Sodium-glucose cotransporter-2 inhibitors in diabetes and beyond: mechanisms, pleiotropic benefits, and clinical use\u2014reviewing protective effects exceeding glycemic control. Molecules 30:4125. https:\/\/doi.org\/10.3390\/molecules30204125","journal-title":"Molecules"},{"key":"12564_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","volume":"9","author":"SA Lee","year":"2024","unstructured":"Lee SA, Riella LV (2024) Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers. Kidney Int Rep 9:1601\u20131613. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1435","journal-title":"Kidney Int Rep"},{"key":"12564_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, Rim JH, Hwang I, Lee CJ, Lee M, Oh C-M, Jeon JY, Gee HY, Kim J-H, Lee B-W, Kang ES, Cha B-S, Lee M-S, Yu J-W, Cho JW, Kim J-S, Lee Y (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"12564_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee N, Heo YJ, Choi S-E, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res 2021:1\u201311. https:\/\/doi.org\/10.1155\/2021\/9944880","journal-title":"J Immunol Res"},{"key":"12564_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM (2021) SGLT2 inhibitors: physiology and pharmacology. Kidney360 2:2027\u20132037. https:\/\/doi.org\/10.34067\/KID.0002772021","journal-title":"Kidney360"},{"key":"12564_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL (2018) Human T cell development, localization, and function throughout life. Immunity 48:202\u2013213. https:\/\/doi.org\/10.1016\/j.immuni.2018.01.007","journal-title":"Immunity"},{"key":"12564_CR8","doi-asserted-by":"publisher","unstructured":"M. Koutentakis, J. Kuci\u0144ski, D. \u015awieczkowski, S. Surma, K.J. Filipiak, A. G\u0105secka, The Ketogenic Effect of SGLT-2 Inhibitors\u2014Beneficial or Harmful?, J. Cardiovasc. Dev. Dis. 10 (2023) 465. https:\/\/doi.org\/10.3390\/jcdd10110465.","DOI":"10.3390\/jcdd10110465."},{"key":"12564_CR9","doi-asserted-by":"publisher","unstructured":"Y.J.M. Op Den Kamp, A. Gemmink, M. De Ligt, B. Dautzenberg, E. Kornips, J.A. Jorgensen, G. Schaart, R. Esterline, D.A. Pava, J. Hoeks, V.B. Schrauwen-Hinderling, S. Kersten, B. Havekes, T.R. Koves, D.M. Muoio, M.K.C. Hesselink, J. Oscarsson, E. Phielix, P. Schrauwen, Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism, Mol. Metab. 66 (2022) 101620. https:\/\/doi.org\/10.1016\/j.molmet.2022.101620.","DOI":"10.1016\/j.molmet.2022.101620."},{"key":"12564_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/intimm\/dxac025","volume":"34","author":"Y Endo","year":"2022","unstructured":"Endo Y, Kanno T, Nakajima T (2022) Fatty acid metabolism in T-cell function and differentiation. Int Immunol 34:579\u2013587. https:\/\/doi.org\/10.1093\/intimm\/dxac025","journal-title":"Int Immunol"},{"key":"12564_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1084\/jem.20151159","volume":"212","author":"MD Buck","year":"2015","unstructured":"Buck MD, O\u2019Sullivan D, Pearce EL (2015) T cell metabolism drives immunity. J Exp Med 212:1345\u20131360. https:\/\/doi.org\/10.1084\/jem.20151159","journal-title":"J Exp Med"},{"key":"12564_CR12","doi-asserted-by":"publisher","unstructured":"Z. Jin, H. Hammoud, A.K. Bhandage, S. Koreli, A.I. Chowdhury, P. Bergsten, B. Birnir, Inhibition of the Na+-glucose transporter SGLT2 reduces glucose uptake and IFN\u03b3 release from activated human CD4\u2009+\u2009T cells, Front. Immunol. 16 (2025) 1576216. https:\/\/doi.org\/10.3389\/fimmu.2025.1576216.","DOI":"10.3389\/fimmu.2025.1576216."},{"key":"12564_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185218","volume":"135","author":"P Mart\u00edn","year":"2025","unstructured":"Mart\u00edn P, S\u00e1nchez-Madrid F (2025) T cells in cardiac health and disease. J Clin Invest 135:e185218. https:\/\/doi.org\/10.1172\/JCI185218","journal-title":"J Clin Invest"},{"key":"12564_CR14","doi-asserted-by":"publisher","unstructured":"S. Dellepiane, J.S. Leventhal, P. Cravedi, T Cells and Acute Kidney Injury: A Two-Way Relationship, Front. Immunol. 11 (2020) 1546. https:\/\/doi.org\/10.3389\/fimmu.2020.01546.","DOI":"10.3389\/fimmu.2020.01546."},{"key":"12564_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498808","volume":"15","author":"Z Liu","year":"2024","unstructured":"Liu Z, Dai B, Bao J, Pan Y (2024) T cell metabolism in kidney immune homeostasis. Front Immunol 15:1498808. https:\/\/doi.org\/10.3389\/fimmu.2024.1498808","journal-title":"Front Immunol"},{"key":"12564_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","volume":"21","author":"S Ma","year":"2024","unstructured":"Ma S, Ming Y, Wu J, Cui G (2024) Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol Immunol 21:419\u2013435. https:\/\/doi.org\/10.1038\/s41423-024-01148-8","journal-title":"Cell Mol Immunol"},{"key":"12564_CR17","doi-asserted-by":"publisher","unstructured":"L.Z. Shi, R. Wang, G. Huang, P. Vogel, G. Neale, D.R. Green, H. Chi, HIF1\u03b1\u2013dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells, J. Exp. Med. 208 (2011) 1367\u20131376. https:\/\/doi.org\/10.1084\/jem.20110278.","DOI":"10.1084\/jem.20110278."},{"key":"12564_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041356","volume":"12","author":"D Semo","year":"2023","unstructured":"Semo D, Obergassel J, Dorenkamp M, Hemling P, Strutz J, Hiden U, M\u00fcller N, M\u00fcller UA, Zulfikar SA, Godfrey R, Waltenberger J (2023) The sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reverses hyperglycemia-induced monocyte and endothelial dysfunction primarily through glucose transport-independent but redox-dependent mechanisms. J Clin Med 12:1356. https:\/\/doi.org\/10.3390\/jcm12041356","journal-title":"J Clin Med"},{"key":"12564_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.18293","volume":"198","author":"J Qin","year":"2022","unstructured":"Qin J, Liu Q, Liu A, Leng S, Wang S, Li C, Ma J, Peng J, Xu M (2022) Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia. Br J Haematol 198:765\u2013775. https:\/\/doi.org\/10.1111\/bjh.18293","journal-title":"Br J Haematol"},{"key":"12564_CR20","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","volume":"35","author":"BJ Jenkins","year":"2023","unstructured":"Jenkins BJ, Blagih J, Ponce-Garcia FM, Canavan M, Gudgeon N, Eastham S, Hill D, Hanlon MM, Ma EH, Bishop EL, Rees A, Cronin JG, Jury EC, Dimeloe SK, Veale DJ, Thornton CA, Vousden KH, Finlay DK, Fearon U, Jones GW, Sinclair LV, Vincent EE, Jones N (2023) Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell Metab 35:1132-1146.e9. https:\/\/doi.org\/10.1016\/j.cmet.2023.05.001","journal-title":"Cell Metab"},{"key":"12564_CR21","doi-asserted-by":"publisher","unstructured":"Y. Shi, H. Zhang, C. Miao, Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives, Cell Death Discov. 11 (2025) 123. https:\/\/doi.org\/10.1038\/s41420-025-02403-1.","DOI":"10.1038\/s41420-025-02403-1."},{"key":"12564_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.molimm.2015.07.036","volume":"68","author":"M Slack","year":"2015","unstructured":"Slack M, Wang T, Wang R (2015) T cell metabolic reprogramming and plasticity. Mol Immunol 68:507\u2013512. https:\/\/doi.org\/10.1016\/j.molimm.2015.07.036","journal-title":"Mol Immunol"},{"key":"12564_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.azn.2025.02.006","volume":"1","author":"Z Ji","year":"2025","unstructured":"Ji Z, Yang W, Li S, Chang Y, Yang T, Luan Y, Chen S, Yin Y, Xu C, Zhang B (2025) Regulation of immune metabolism in Th17 and Treg cells. Animals and Zoonoses 1:266\u2013275. https:\/\/doi.org\/10.1016\/j.azn.2025.02.006","journal-title":"Animals and Zoonoses"},{"key":"12564_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678355","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Gang X, Yang S, Cui M, Sun L, Li Z, Wang G (2021) The alterations in and the role of the Th17\/Treg balance in metabolic diseases. Front Immunol 12:678355. https:\/\/doi.org\/10.3389\/fimmu.2021.678355","journal-title":"Front Immunol"},{"key":"12564_CR25","doi-asserted-by":"publisher","unstructured":"X. Xie, Y. Liu, H. Li, The Th17\/Treg axis: a key to understanding and treating autoimmune disorders, Open Life Sci. 21 (2026) 20251285. https:\/\/doi.org\/10.1515\/biol-2025-1285.","DOI":"10.1515\/biol-2025-1285."},{"key":"12564_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1042\/EBC20240007","volume":"68","author":"WJ Smiles","year":"2024","unstructured":"Smiles WJ, Ovens AJ, Kemp BE, Galic S, Petersen J, Oakhill JS (2024) New developments in AMPK and mTORC1 cross-talk. Essays Biochem 68:321\u2013336. https:\/\/doi.org\/10.1042\/EBC20240007","journal-title":"Essays Biochem"},{"key":"12564_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010037","volume":"23","author":"A Ara","year":"2021","unstructured":"Ara A, Xu A, Ahmed KA, Leary SC, Islam M, Wu Z, Chibbar R, Xiang J (2021) The energy sensor AMPK\u03b11 is critical in rapamycin-inhibition of mTORC1-S6K-induced T-cell memory. Int J Mol Sci 23:37. https:\/\/doi.org\/10.3390\/ijms23010037","journal-title":"Int J Mol Sci"},{"key":"12564_CR28","doi-asserted-by":"publisher","unstructured":"J. Li, C. Zhang, Y. Hu, J. Peng, Q. Feng, X. Hu, Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia, Br. J. Haematol. 205 (2024) 2432\u20132441. https:\/\/doi.org\/10.1111\/bjh.19820.","DOI":"10.1111\/bjh.19820."},{"key":"12564_CR29","doi-asserted-by":"publisher","unstructured":"\u00a0J. Van Loosdregt, Y. Vercoulen, T. Guichelaar, Y.Y.J. Gent, J.M. Beekman, O. Van Beekum, A.B. Brenkman, D.-J. Hijnen, T. Mutis, E. Kalkhoven, B.J. Prakken, P.J. Coffer, Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization, Blood 115 (2010) 965\u2013974. https:\/\/doi.org\/10.1182\/blood-2009-02-207118.","DOI":"10.1182\/blood-2009-02-207118."},{"key":"12564_CR30","doi-asserted-by":"publisher","unstructured":"X. Bian, H. Xue, D. Jing, Y. Wang, G. Zhou, F. Zhu, Role of Serum\/Glucocorticoid-Regulated Kinase 1 (SGK1) in Immune and Inflammatory Diseases, Inflammation 46 (2023) 1612\u20131625. https:\/\/doi.org\/10.1007\/s10753-023-01857-8.","DOI":"10.1007\/s10753-023-01857-8."},{"key":"12564_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2174\/1573399814666180813124645","volume":"15","author":"E Cersosimo","year":"2019","unstructured":"Cersosimo E, Miles JM (2019) Hormonal, metabolic and hemodynamic adaptations to glycosuria in type 2 diabetes patients treated with sodium-glucose co-transporter inhibitors. Curr Diabetes Rev 15:314\u2013327. https:\/\/doi.org\/10.2174\/1573399814666180813124645","journal-title":"Curr Diabetes Rev"},{"key":"12564_CR32","doi-asserted-by":"publisher","unstructured":"M. Packer, SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action, Diabetes Care 43 (2020) 508\u2013511. https:\/\/doi.org\/10.2337\/dci19-0074.","DOI":"10.2337\/dci19-0074."},{"key":"12564_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111279","volume":"27","author":"Z Li","year":"2024","unstructured":"Li Z, Duan R, Jiang Q, Liu J, Chen J, Jiang L, Wang T, Li H, Zhang Y, Peng X, Huang Z, Zhu L, Zou W, Lin Y, Su W (2024) Dietary caloric restriction protects experimental autoimmune uveitis by regulating Teff\/Treg balance. iScience 27:111279. https:\/\/doi.org\/10.1016\/j.isci.2024.111279","journal-title":"iScience"},{"key":"12564_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.advnut.2023.07.006","volume":"14","author":"R Shabkhizan","year":"2023","unstructured":"Shabkhizan R, Haiaty S, Moslehian MS, Bazmani A, Sadeghsoltani F, Bagheri HS, Rahbarghazi R, Sakhinia E (2023) The beneficial and adverse effects of autophagic response to caloric restriction and fasting. Adv Nutr 14:1211\u20131225. https:\/\/doi.org\/10.1016\/j.advnut.2023.07.006","journal-title":"Adv Nutr"},{"key":"12564_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102331","volume":"6","author":"J Zhang","year":"2025","unstructured":"Zhang J, Cai W, Liu D, Zheng N, Wang Y, Qiu F, Zheng H, Gan H, Huang Y, Zhou Y, Yu M, Xiong S, Luo G, Guo J, Zhu L, Zhang Y, Ke H, Liu Y, Huang G, Yu C, Li C, Hu L, Xu J (2025) Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: a multicenter, randomized, double-blind, placebo-controlled study. Cell Rep Med 6:102331. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102331","journal-title":"Cell Rep Med"},{"key":"12564_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s42255-021-00356-0","volume":"3","author":"K Han","year":"2021","unstructured":"Han K, Singh K, Rodman MJ, Hassanzadeh S, Wu K, Nguyen A, Huffstutler RD, Seifuddin F, Dagur PK, Saxena A, McCoy JP, Chen J, Biancotto A, Stagliano KER, Teague HL, Mehta NN, Pirooznia M, Sack MN (2021) Fasting-induced FOXO4 blunts human CD4+ T helper cell responsiveness. Nat Metab 3:318\u2013326. https:\/\/doi.org\/10.1038\/s42255-021-00356-0","journal-title":"Nat Metab"},{"key":"12564_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/eji.201646423","volume":"47","author":"S Cohen","year":"2017","unstructured":"Cohen S, Danzaki K, MacIver NJ (2017) Nutritional effects on T-cell immunometabolism. Eur J Immunol 47:225\u2013235. https:\/\/doi.org\/10.1002\/eji.201646423","journal-title":"Eur J Immunol"},{"key":"12564_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cmet.2013.12.008","volume":"19","author":"VD Longo","year":"2014","unstructured":"Longo VD, Mattson MP (2014) Fasting: molecular mechanisms and clinical applications. Cell Metab 19:181\u2013192. https:\/\/doi.org\/10.1016\/j.cmet.2013.12.008","journal-title":"Cell Metab"},{"issue":"1","key":"12564_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s40200-025-01824-0","volume":"25","author":"K Hushmandi","year":"2026","unstructured":"Hushmandi K, Salarizadeh N, Einollahi B, Izadi M, Doosti P, Behzadnia MJ, Cho WC, Yousefi T, Khoshnazar SM, Alimohammadi M, Farahani N (2026) SGLT2 inhibitors and AMPK crosstalk in diabetes mellitus: mechanistic insights and therapeutic applications. J Diabetes Metab Disord 25:114. https:\/\/doi.org\/10.1007\/s40200-025-01824-0","journal-title":"J Diabetes Metab Disord"},{"key":"12564_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0273-y","volume":"9","author":"PF Secker","year":"2018","unstructured":"Secker PF, Beneke S, Schlichenmaier N, Delp J, Gutbier S, Leist M, Dietrich DR (2018) Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis 9:226. https:\/\/doi.org\/10.1038\/s41419-018-0273-y","journal-title":"Cell Death Dis"},{"key":"12564_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT (2017) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24:73\u201379. https:\/\/doi.org\/10.1097\/MED.0000000000000311","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"12564_CR42","doi-asserted-by":"publisher","unstructured":"Q. Lu, X. Li, J. Liu, X. Sun, T. Rousselle, D. Ren, N. Tong, J. Li, AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases, Biosci. Rep. 39 (2019) BSR20181995. https:\/\/doi.org\/10.1042\/BSR20181995.","DOI":"10.1042\/BSR20181995."},{"key":"12564_CR43","doi-asserted-by":"publisher","first-page":"608","DOI":"10.17305\/bb.2024.11361","volume":"25","author":"W-C Lee","year":"2024","unstructured":"Lee W-C, Lin Y-W, Shih J-Y, Chen Z-C, Wu N-C, Chang W-T, Liu P-Y (2024) Dapagliflozin and Sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model. Biomolecules Biomed 25:608\u2013622. https:\/\/doi.org\/10.17305\/bb.2024.11361","journal-title":"Biomolecules Biomed"},{"key":"12564_CR44","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.celrep.2017.12.068","volume":"22","author":"C Wu","year":"2018","unstructured":"Wu C, Chen Z, Xiao S, Thalhamer T, Madi A, Han T, Kuchroo V (2018) SGK1 governs the reciprocal development of Th17 and regulatory T cells. Cell Rep 22:653\u2013665. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.068","journal-title":"Cell Rep"},{"key":"12564_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112156","volume":"584","author":"D Wang","year":"2024","unstructured":"Wang D, Zhang Q, Dong W, Ren S, Wang X, Su C, Lin X, Zheng Z, Xue Y (2024) SGLT2 knockdown restores the Th17\/Treg balance and suppresses diabetic nephropathy in db\/db mice by regulating SGK1 via Na+. Mol Cell Endocrinol 584:112156. https:\/\/doi.org\/10.1016\/j.mce.2024.112156","journal-title":"Mol Cell Endocrinol"},{"key":"12564_CR46","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/2211-5463.13147","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhang Z, Si Z, Yang Y, Li S, Xue Y (2021) Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. FEBS Open Bio 11:1395\u20131405. https:\/\/doi.org\/10.1002\/2211-5463.13147","journal-title":"FEBS Open Bio"},{"key":"12564_CR47","doi-asserted-by":"publisher","unstructured":"A.P. Vargas-Delgado, E. Arteaga Herrera, C. Tumbaco Mite, P. Delgado Cedeno, M.C. Van Loon, J.J. Badimon, Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors, Int. J. Mol. Sci. 24 (2023) 4144. https:\/\/doi.org\/10.3390\/ijms24044144.","DOI":"10.3390\/ijms24044144."},{"key":"12564_CR48","doi-asserted-by":"publisher","unstructured":"Y.-H. Youm, K.Y. Nguyen, R.W. Grant, E.L. Goldberg, M. Bodogai, D. Kim, D. D\u2019Agostino, N. Planavsky, C. Lupfer, T.D. Kanneganti, S. Kang, T.L. Horvath, T.M. Fahmy, P.A. Crawford, A. Biragyn, E. Alnemri, V.D. Dixit, The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease, Nat. Med. 21 (2015) 263\u2013269. https:\/\/doi.org\/10.1038\/nm.3804.","DOI":"10.1038\/nm.3804."},{"key":"12564_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1214289","volume":"14","author":"TSB Honda","year":"2023","unstructured":"Honda TSB, Ku J, Anders H-J (2023) Cell type-specific roles of NLRP3, inflammasome-dependent and -independent, in host defense, sterile necroinflammation, tissue repair, and fibrosis. Front Immunol 14:1214289. https:\/\/doi.org\/10.3389\/fimmu.2023.1214289","journal-title":"Front Immunol"},{"key":"12564_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.70050","volume":"126","author":"S Ehtiati","year":"2025","unstructured":"Ehtiati S, Hatami B, Khatami SH, Tajernarenj K, Abdi S, Sirati-Sabet M, Ghazizadeh Hashemi SAH, Ahmadzade R, Hamed N, Goudarzi M, Namvarjah F, Hajimohammadebrahim\u2010Ketabforoush M, Tafakhori A, Aghamollaii V, Karima S (2025) The multifaceted influence of beta\u2010hydroxybutyrate on autophagy, mitochondrial metabolism, and epigenetic regulation. J Cell Biochem 126:e70050. https:\/\/doi.org\/10.1002\/jcb.70050","journal-title":"J Cell Biochem"},{"key":"12564_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21098","volume":"9","author":"Y He","year":"2023","unstructured":"He Y, Cheng X, Zhou T, Li D, Peng J, Xu Y, Huang W (2023) \u03b2-Hydroxybutyrate as an epigenetic modifier: underlying mechanisms and implications. Heliyon 9:e21098. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21098","journal-title":"Heliyon"},{"key":"12564_CR52","doi-asserted-by":"publisher","unstructured":"\u00a0A. Ferrari, J. Filoni, C. Di Dedda, L. Piemonti, P. Monti, Ketone bodies rescue T cell impairments induced by low glucose availability, Eur. J. Nutr. 63 (2024) 2815\u20132825. https:\/\/doi.org\/10.1007\/s00394-024-03469-w.","DOI":"10.1007\/s00394-024-03469-w."},{"key":"12564_CR53","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/s42255-025-01415-6","volume":"7","author":"BM Oswald","year":"2025","unstructured":"Oswald BM, DeCamp LM, Longo J, Dahabieh MS, Bunda N, Johnson BK, Watson MJ, Ma S, Preston SEJ, Sheldon RD, Vincent MP, Ellis AE, Soper-Hopper MT, Isaguirre C, Kamarudin D, Shen H, Williams KS, Crawford PA, Kaech S, Jang HJ, Lien EC, Krawczyk CM, Jones RG (2025) Dietary restriction reprograms CD8\u2009+\u2009T cell fate to enhance anti-tumour immunity and immunotherapy responses. Nat Metab 7:2489\u20132509. https:\/\/doi.org\/10.1038\/s42255-025-01415-6","journal-title":"Nat Metab"},{"key":"12564_CR54","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.immuni.2023.07.002","volume":"56","author":"KM Luda","year":"2023","unstructured":"Luda KM, Longo J, Kitchen-Goosen SM, Duimstra LR, Ma EH, Watson MJ, Oswald BM, Fu Z, Madaj Z, Kupai A, Dickson BM, DeCamp LM, Dahabieh MS, Compton SE, Teis R, Kaymak I, Lau KH, Kelly DP, Puchalska P, Williams KS, Krawczyk CM, L\u00e9vesque D, Boisvert F-M, Sheldon RD, Rothbart SB, Crawford PA, Jones RG (2023) Ketolysis drives CD8\u2009+\u2009T cell effector function through effects on histone acetylation. Immunity 56:2021-2035.e8. https:\/\/doi.org\/10.1016\/j.immuni.2023.07.002","journal-title":"Immunity"},{"key":"12564_CR55","doi-asserted-by":"publisher","unstructured":"X.-Y. Han, Z.-Y. Li, S.-F. Chen, M.-H. Zhao, M.A. Little, M. Chen, Canagliflozin Alleviates Experimental Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis through Suppression of Pathogenic T-Cell Responses, J. Am. Soc. Nephrol. (2026). https:\/\/doi.org\/10.1681\/ASN.0000001137.","DOI":"10.1681\/ASN.0000001137."},{"key":"12564_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109024","volume":"110","author":"Q Long","year":"2022","unstructured":"Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, Tang Y, Liu C, Yuan J (2022) SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol 110:109024. https:\/\/doi.org\/10.1016\/j.intimp.2022.109024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"12564_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2026.168185","volume":"1872","author":"Y Wu","year":"2026","unstructured":"Wu Y, Ge X, Yu D, Wu Y, Shi C, Cai W, Liao Y, Huang L, Ge F, Song W, Xu M, Guo A, Shi T, Luo Q, Lu Y, Gao S (2026) Dapagliflozin targets ROR\u03b3t to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4\u2009+\u2009T cell\/Th17 cell axis within cardiac tissue. Biochimica et Biophysica Acta (BBA) 1872(4):168185. https:\/\/doi.org\/10.1016\/j.bbadis.2026.168185","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"12564_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107492","volume":"94","author":"Z Meng","year":"2021","unstructured":"Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, Sun B, Chen L (2021) The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway. Int Immunopharmacol 94:107492. https:\/\/doi.org\/10.1016\/j.intimp.2021.107492","journal-title":"Int Immunopharmacol"},{"key":"12564_CR59","doi-asserted-by":"publisher","unstructured":"A.H. Abbas, Z.H. Abbas, H.R. Salman, H.E. Jabar, A. H. Abd, Attenuated Effects of Topical Empagliflozin on Imiquimod-induced Model of Psoriasis in Mice: The attenuated effects of Topical Empagliflozin on Imiquimod-induced Model of Psoriasis in Mice, J. Trop. Life Sci. 14 (2024). https:\/\/doi.org\/10.11594\/jtls.14.03.03.","DOI":"10.11594\/jtls.14.03.03."},{"key":"12564_CR60","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.humimm.2021.03.004","volume":"82","author":"S Borzouei","year":"2021","unstructured":"Borzouei S, Moghimi H, Zamani A, Behzad M (2021) Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol 82:422\u2013428. https:\/\/doi.org\/10.1016\/j.humimm.2021.03.004","journal-title":"Hum Immunol"},{"key":"12564_CR61","doi-asserted-by":"publisher","unstructured":"H. Xiao, X. Zeng, Q. Pang, H. Chen, S. Lai, The effect of SGLT2 inhibition on immune cells and transplant rejection\/failure: A drug-targeted mendelian randomization study, Transpl. Immunol. 96 (2026) 102385. https:\/\/doi.org\/10.1016\/j.trim.2026.102385.","DOI":"10.1016\/j.trim.2026.102385."},{"key":"12564_CR62","doi-asserted-by":"publisher","unstructured":"\u00a0G.R. Lee, The Balance of Th17 versus Treg Cells in Autoimmunity, Int. J. Mol. Sci. 19 (2018) 730. https:\/\/doi.org\/10.3390\/ijms19030730.","DOI":"10.3390\/ijms19030730."},{"key":"12564_CR63","doi-asserted-by":"publisher","unstructured":"T. Luo, L. Zhang, K. Tu, G. Li, H. Su, G. Gong, Y. Huang, M. Li, X. Yang, SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges, Front. Immunol. 16 (2025) 1589341. https:\/\/doi.org\/10.3389\/fimmu.2025.1589341.","DOI":"10.3389\/fimmu.2025.1589341."},{"key":"12564_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085196","volume":"391","author":"B Hong","year":"2025","unstructured":"Hong B, Lee H, Jung K, Rhee SY, Yon DK, Shin J-Y (2025) Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study. BMJ 391:e085196. https:\/\/doi.org\/10.1136\/bmj-2025-085196","journal-title":"BMJ"},{"key":"12564_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002686","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Li T, Sun F, Liu Z, Zhang D, Teng X, Morel L, Wang X, Ye S (2022) Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial. RMD Open 8:e002686. https:\/\/doi.org\/10.1136\/rmdopen-2022-002686","journal-title":"RMD Open"},{"key":"12564_CR66","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.jaad.2026.02.008","volume":"94","author":"D Cheng","year":"2026","unstructured":"Cheng D, Ji H, Theodosakis N, Noe MH, Chen ST, Ma K-K (2026) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: a population-based target trial emulation. J Am Acad Dermatol 94:1686\u20131696. https:\/\/doi.org\/10.1016\/j.jaad.2026.02.008","journal-title":"J Am Acad Dermatol"},{"key":"12564_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000551255","volume":"6","author":"G Vajgel","year":"2026","unstructured":"Vajgel G, S\u00e4emann MD, Kronbichler A (2026) Sodium-glucose cotransporter 2 inhibitors in lupus nephritis and ANCA-associated vasculitis: unmet needs to be addressed. Glomerular Dis 6:139\u2013156. https:\/\/doi.org\/10.1159\/000551255","journal-title":"Glomerular Dis"},{"key":"12564_CR68","doi-asserted-by":"publisher","unstructured":"Y. Xia, D. Gao, X. Wang, B. Liu, X. Shan, Y. Sun, D. Ma, Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets, Front. Immunol. 15 (2024) 1331609. https:\/\/doi.org\/10.3389\/fimmu.2024.1331609.","DOI":"10.3389\/fimmu.2024.1331609."},{"key":"12564_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1126761","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Zhou H, Liu Q, Cheng P, Zhao T, Yang T, Zhao Y, Sha W, Zhao Y, Qu H (2023) Targeting regulatory T cells for cardiovascular diseases. Front Immunol 14:1126761. https:\/\/doi.org\/10.3389\/fimmu.2023.1126761","journal-title":"Front Immunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12564-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:47:18Z","timestamp":1786625238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12564-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12564"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12564-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"4 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review and does not contain any studies with human participants or animals performed by either author.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT solely for linguistic refinement and stylistic editing. All scientific concepts, mechanistic interpretations, and translational conclusions were independently developed and verified by the authors, who retain full responsibility for the accuracy and integrity of the work.","order":5,"name":"Ethics","label":"AI and AI-Assisted Technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1394"}}